<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089685</url>
  </required_header>
  <id_info>
    <org_study_id>3475-029</org_study_id>
    <secondary_id>2013-004072-36</secondary_id>
    <nct_id>NCT02089685</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)</brief_title>
  <official_title>A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to analyze the safety, tolerability, and efficacy of treatment for&#xD;
      advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of&#xD;
      pembrolizumab + pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab + ipilimumab&#xD;
      (IPI). The primary hypothesis is that these combinations will be sufficiently well-tolerated&#xD;
      to permit continued clinical investigation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is being done in three parts: Part 1A (MEL and RCC) will define the maximum&#xD;
      tolerated dose (MTD)/maximum administered dose (MAD) for the drug combinations; a recommended&#xD;
      Phase 2 dose (RP2D) for each combination will be identified. Part 1B (MEL-single arm&#xD;
      expansion) will better characterize safety and efficacy and provide preliminary efficacy data&#xD;
      for the penbrolizumab + IPI combination in participants with MEL. Part 2 (MEL and RCC) is a&#xD;
      randomized portion of the trial and will evaluate preliminary efficacy of the drug&#xD;
      combinations given in 6-week cycles for advanced MEL participants. Part 2 was removed from&#xD;
      the study with Amendment 3 of the protocol. Part 1C (MEL) is added as the third part of the&#xD;
      study with Amendment 3. Part 1C will evaluate safety and efficacy for different doses and&#xD;
      dosing intervals for IPI in combination with pembrolizumab in participants with advanced MEL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2014</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicities (Part 1A)</measure>
    <time_frame>Up to 6 weeks (Cycle 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events (AEs)</measure>
    <time_frame>Up to 27 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study drug because of AEs</measure>
    <time_frame>Up to 24 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) (Part 2)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing grade 3-5 drug-related AEs (Part 1C)</measure>
    <time_frame>Up to 27 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) (Part 1C)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Part 1C)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Part 2)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) (Parts 1B, 1C)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Parts 1B, 1C)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Parts 1B, 1C)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing grade 3-4 AEs</measure>
    <time_frame>Up to 27 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR using RECIST 1.1 (Part 1B)</measure>
    <time_frame>Up to 24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + PegIFN-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part A receive pembrolizumab intravenously (IV) at assigned dose every 3 weeks + PegIFN-2b subcutaneously (SC) at assigned dose once a week in each 6-week cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + IPI Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Parts 1A and 1B receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 1 mg/kg every 3 weeks (Q3W) for a total of two 6-week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + IPI Q6W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 50 mg every 6 weeks (Q6W) for a maximum of four 6-week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + IPI Q12W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 100 mg every 12 weeks (Q12W) for a maximum of eight 6-week cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Pembrolizumab + IPI Q12W</arm_group_label>
    <arm_group_label>Pembrolizumab + IPI Q3W</arm_group_label>
    <arm_group_label>Pembrolizumab + IPI Q6W</arm_group_label>
    <arm_group_label>Pembrolizumab + PegIFN-2b</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PegIFN-2b</intervention_name>
    <arm_group_label>Pembrolizumab + PegIFN-2b</arm_group_label>
    <other_name>PegIntron®</other_name>
    <other_name>Sylatron®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Pembrolizumab + IPI Q12W</arm_group_label>
    <arm_group_label>Pembrolizumab + IPI Q3W</arm_group_label>
    <arm_group_label>Pembrolizumab + IPI Q6W</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically- or cytologically-confirmed diagnosis of advanced/unresectable or&#xD;
             metastatic MEL or RCC (Part 1A only) with predominantly clear cell elements&#xD;
&#xD;
          -  Previously untreated stage III/IV advanced or metastatic MEL (Part 1C only)&#xD;
&#xD;
          -  MEL subjects may be treatment naïve or may have received prior lines of therapy for&#xD;
             metastatic disease (Parts 1A and 1B)&#xD;
&#xD;
          -  RCC subjects must have received ≥1 prior line of therapy for metastatic disease (Part&#xD;
             1A)&#xD;
&#xD;
          -  Measurable disease as defined by RECIST 1.1&#xD;
&#xD;
          -  Must provide a tumor sample (archival or newly obtained biopsy) that is adequate for&#xD;
             determination of PD (programmed cell death)-Ligand 1 status by immunohistochemistry at&#xD;
             a central pathology laboratory prior to enrollment. Note: Adequacy of the tumor sample&#xD;
             for PD-Ligand 1 testing is not required prior to enrollment in Part 1C&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less&#xD;
             (Parts 1A and 1B) and/or recovered from major surgery or radiation therapy&#xD;
&#xD;
          -  Female participants of childbearing potential must be willing to use adequate&#xD;
             contraception during the course of the study through 120 days after the last dose of&#xD;
             study drug&#xD;
&#xD;
          -  Male participants must agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Uveal or ocular MEL&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form&#xD;
             of immunosuppressive therapy within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Prior therapy with an anti-programmed cell death (anti-PD)-1, anti-PD-Ligand 1,&#xD;
             anti-PD-Ligand 2 or with an agent directed to another co-inhibitory T-cell receptor or&#xD;
             has previously participated in a pembrolizumab clinical trial. Note: In Part 1C,&#xD;
             participants may have received anti-PD-1 and/or anti-Cytotoxic T-lymphocyte-associated&#xD;
             antigen 4 (anti-CTLA-4) as part of their neo/adjuvant treatment.&#xD;
&#xD;
          -  Has received prior anti-cancer therapy, monoclonal antibody, chemotherapy, or an&#xD;
             investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)&#xD;
             before first dose of trial drug or not recovered (≤ Grade 1 or at baseline) from AEs&#xD;
             due to previously administered agents (Parts 1A and 1B)&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing&#xD;
             exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive&#xD;
             therapy within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment with the&#xD;
             exception of early stage cancers (carcinoma in situ or Stage 1) treated with curative&#xD;
             intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in&#xD;
             situ cervical cancer or in situ breast cancer that has undergone potentially curative&#xD;
             therapy&#xD;
&#xD;
          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  Severe hypersensitivity to any pembrolizumab excipients&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment in the past 2 years&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial from screening through 120 days after the last dose of&#xD;
             study drug&#xD;
&#xD;
          -  Prior therapy with interferon alfa (in neoadjuvant, adjuvant, or metastatic settings)&#xD;
             (Part 1A only)&#xD;
&#xD;
          -  Uncontrolled thyroid dysfunction&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Known history of or is positive for Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Received a live vaccine within 30 days prior to first dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>New Zealand</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://merckoncologyclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trials Information</description>
  </link>
  <results_reference>
    <citation>Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.</citation>
    <PMID>28729151</PMID>
  </results_reference>
  <results_reference>
    <citation>Carlino MS, Menzies AM, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Guminski AD, Kefford R, Wu H, Ibrahim N, Homet Moreno B, Long GV. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 Oct 1;26(19):5086-5091. doi: 10.1158/1078-0432.CCR-20-0177. Epub 2020 Jun 30.</citation>
    <PMID>32605909</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

